摘要: Hintergrund Knochenmetastasen kommen haufig beim fortgeschrittenen Mamma- und Prostatakarzinomen vor, Osteolysen sind wiederum typisch multiplen Myelom. Knochenerkrankungen durch Metastasen bedeutende Ursachen der Morbiditat bei Krebs. Tumorzellen konnen sich in den Nischen hamatopoetischen Stammzellen absiedeln dort lange Zeit ruhen, bevor sie zu erkennbaren weiterentwickeln. Die zellularen Interaktionen im Knochenmark von groser Bedeutung ruhenden Metastasierung. osteolytische Knochenzerstorung entsteht Osteoklasten, die tumorassoziierte Zytokine stimuliert werden.
springer.com
sci-hub.se 参考文章(31)
Rahul Mhaskar, Jasmina Redzepovic, Keith Wheatley, Otavio Augusto Camara Clark, Branko Miladinovic, Axel Glasmacher, Ambuj Kumar, Benjamin Djulbegovic, Bisphosphonates in multiple myeloma: a network meta‐analysis Cochrane Database of Systematic Reviews. ,vol. 5, ,(2012) , 10.1002/14651858.CD003188.PUB3
Rosandra N. Kaplan, Shahin Rafii, David Lyden, Preparing the “Soil”: The Premetastatic Niche: Figure 1. Cancer Research. ,vol. 66, pp. 11089- 11093 ,(2006) , 10.1158/0008-5472.CAN-06-2407
Lee S. Rosen, David Gordon, N. Simon Tchekmedyian, Ronald Yanagihara, Vera Hirsh, Maciej Krzakowski, Marek Pawlicki, Paul de Souza, Ming Zheng, Gladys Urbanowitz, Dirk Reitsma, John Seaman, , Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors Cancer. ,vol. 100, pp. 2613- 2621 ,(2004) , 10.1002/CNCR.20308
Katherine N. Weilbaecher, Theresa A. Guise, Laurie K. McCauley, Cancer to bone: a fatal attraction Nature Reviews Cancer. ,vol. 11, pp. 411- 425 ,(2011) , 10.1038/NRC3055
Michael P. Whyte, The long and the short of bone therapy. The New England Journal of Medicine. ,vol. 354, pp. 860- 863 ,(2006) , 10.1056/NEJME068003
Peter Gimsing, Kristina Carlson, Ingemar Turesson, Peter Fayers, Anders Waage, Annette Vangsted, Anne Mylin, Christian Gluud, Gunnar Juliusson, Henrik Gregersen, Henrik Hjorth-Hansen, Ingerid Nesthus, Inger Marie S Dahl, Jan Westin, Johan Lanng Nielsen, Lene Meldgaard Knudsen, Lucia Ahlberg, Martin Hjorth, Niels Abildgaard, Niels Frost Andersen, Olle Linder, Finn Wisløff, Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial Lancet Oncology. ,vol. 11, pp. 973- 982 ,(2010) , 10.1016/S1470-2045(10)70198-4
Dino Amadori, Massimo Aglietta, Barbara Alessi, Lorenzo Gianni, Toni Ibrahim, Gabriella Farina, Fernando Gaion, Francesco Bertoldo, Daniele Santini, Roberta Rondena, Paola Bogani, Carla I Ripamonti, Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncology. ,vol. 14, pp. 663- 670 ,(2013) , 10.1016/S1470-2045(13)70174-8
David Henry, Saroj Vadhan-Raj, Vera Hirsh, Roger von Moos, Vania Hungria, Luis Costa, Penella J Woll, Giorgio Scagliotti, Geoffrey Smith, Amy Feng, Susie Jun, Roger Dansey, Howard Yeh, Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Supportive Care in Cancer. ,vol. 22, pp. 679- 687 ,(2014) , 10.1007/S00520-013-2022-1
Andrew F. Stewart, Hypercalcemia Associated with Cancer New England Journal of Medicine. ,vol. 352, pp. 373- 379 ,(2005) , 10.1056/NEJMCP042806
Colleen M. Costelloe, Hubert H. Chuang, John E. Madewell, Naoto T. Ueno, Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST Journal of Cancer. ,vol. 1, pp. 80- 92 ,(2010) , 10.7150/JCA.1.80